Why Are LumiraDx Shares Trading Higher Today?

LumiraDx LMDX has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test.
The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
The test is available in the U.S. and Europe under Emergency Use Authorization.
The LumiraDx SARS-CoV-2 Antigen test is a microfluidic test run on the LumiraDx point of care Platform, which scales down. It integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point of care instrument.
Related content: Benzinga's Full FDA Calendar.
Price Action: LMDX shares are up 13.20% at $9.54 during the market session on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.